HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Urology1724 papers

Hormone sensitive prostate cancer

Last edited: 4/24/2026

Overview

Hormone-sensitive prostate cancer (HSPC) refers to prostate cancer that is initially responsive to androgen deprivation therapy (ADT), typically through surgical castration or pharmacological means such as gonadotropin-releasing hormone (GnRH) agonists or antagonists. This condition is clinically significant due to its prevalence and the potential for significant morbidity and mortality if not managed effectively. It predominantly affects older men, with the average age at diagnosis around 66 years. Understanding the nuances of HSPC management is crucial in day-to-day practice to optimize patient outcomes, minimize side effects, and tailor treatments to individual patient profiles. 1 2 6 26

Pathophysiology

Prostate cancer cells are dependent on androgens for growth and survival, primarily testosterone and dihydrotestosterone (DHT). In HSPC, the initial reduction of androgen levels through castration or ADT leads to a temporary response, often characterized by decreased tumor burden and alleviation of symptoms. However, resistance mechanisms can develop over time, including mutations in the androgen receptor (AR), amplification of the AR gene, and activation of alternative signaling pathways that bypass androgen dependence. These molecular changes enable cancer cells to continue proliferating despite low androgen levels, leading to castration-resistant prostate cancer (CRPC). The transition from HSPC to CRPC underscores the importance of early and precise hormonal management to delay or prevent this progression. 2 26 27

Epidemiology

Prostate cancer is the second most common cancer in men globally, with an estimated 1.4 million new cases diagnosed annually. The incidence increases significantly with age, particularly after 65 years, reflecting the disease's prevalence in older populations. Geographic variations exist, with higher incidence rates reported in North America, Western Europe, and Australia compared to Asia and Africa. Risk factors include family history, genetic predispositions (e.g., BRCA mutations), and certain dietary habits. Recent trends show a slight increase in incidence rates, possibly influenced by improved screening practices, although mortality rates have stabilized or declined in many regions due to advances in treatment. 1 6 26 29 32

Clinical Presentation

Patients with hormone-sensitive prostate cancer often present with symptoms related to local tumor growth or metastatic spread. Common symptoms include urinary obstruction (e.g., difficulty urinating, weak stream), bone pain (indicative of metastasis), and less commonly, systemic symptoms like weight loss and fatigue. Atypical presentations can include neurological symptoms if there is metastasis to the spine or other critical areas. Early detection through screening and PSA monitoring is crucial for timely intervention. Red-flag features include rapid symptom progression, significant weight loss, and severe pain, which may necessitate urgent evaluation and management adjustments. 1 2 3 12 16

Diagnosis

The diagnosis of hormone-sensitive prostate cancer typically involves a combination of clinical assessment, biomarker evaluation, and tissue analysis. Key diagnostic steps include:

PSA Testing: Elevated prostate-specific antigen (PSA) levels are often the initial indicator, though PSA velocity and PSA doubling time are also important.

Digital Rectal Examination (DRE): Identifies abnormalities in prostate size and texture.

Prostate Biopsy: Essential for histopathological confirmation. Transperineal biopsy is increasingly favored due to reduced infection risk 5.

Imaging Studies: MRI and bone scans help assess tumor extent and metastasis.

Histopathologic Grading: Gleason score and TNM staging provide prognostic information.

Genomic Testing: Germline and somatic genomic testing can guide personalized treatment strategies 27.

Differential Diagnosis:

Benign Prostatic Hyperplasia (BPH): Differentiated by absence of elevated PSA levels outside normal ranges and lack of malignant cells on biopsy.

Other Malignancies: Metastatic cancers to the prostate or other urological malignancies require careful histopathological differentiation.

Management

First-Line Treatment

Androgen Deprivation Therapy (ADT):

- Gonadotropin-releasing hormone (GnRH) Agonists: E.g., leuprolide 1 mg monthly (initially higher dose loading dose may be required). - GnRH Antagonists: E.g., degarelix 80 mg subcutaneously monthly. - Monitoring: PSA levels every 3-6 months, adjust therapy based on response and side effects. - (Evidence: Strong)

Combined Androgen Blockade: Adding an anti-androgen (e.g., bicalutamide 50 mg daily) to ADT can enhance efficacy in some cases.

- (Evidence: Moderate)

Second-Line Treatment

Chemotherapy: Initiated when ADT alone is no longer effective.

- Docetaxel: 75 mg/m2 intravenously every 3 weeks for 6 cycles. - Abiraterone Acetate: 1000 mg daily with prednisone 5 mg twice daily. - Enzalutamide: 160 mg daily. - (Evidence: Strong)

Refractory or Specialist Escalation

PARP Inhibitors: For patients with DNA repair gene mutations (e.g., BRCA).

- Olaparib: 30 mg twice daily. - (Evidence: Moderate)

Radium-223 (Ra-223): For symptomatic bone metastases.

- Dosing: 50 kBq/kg every 4 weeks for up to 6 cycles. - (Evidence: Moderate)

Contraindications:

Severe hepatic impairment for abiraterone acetate.

Known hypersensitivity to drugs like enzalutamide.

Complications

Acute Complications:

- Orthostatic Hypotension: Common with GnRH agonists; monitor blood pressure regularly. - Hot Flashes: Manage with non-hormonal therapies like venlafaxine or gabapentin. - (Evidence: Moderate)

Long-Term Complications:

- Osteoporosis: Monitor bone density and consider bisphosphonates. - Cognitive Impairment: Regular cognitive assessments, especially in long-term ADT users. - Cardiovascular Events: Increased risk; monitor cardiovascular health closely. - (Evidence: Moderate)

Prognosis & Follow-Up

The prognosis of HSPC varies widely based on factors such as Gleason score, PSA levels, and extent of disease. Prognostic indicators include:

Gleason Score: Higher scores correlate with poorer outcomes.

PSA Nadir: Lower nadirs post-ADT suggest better prognosis.

Metastatic Status: Presence of metastases significantly impacts survival.

Follow-Up Intervals:

Initial Phase: Monthly PSA checks, then every 3-6 months.

Stabilized Disease: Every 6-12 months.

Advanced Disease: More frequent monitoring based on clinical status.

(Evidence: Moderate)

Special Populations

Elderly Patients: Tailor treatment intensity considering comorbidities and functional status.

Comorbidities: Manage cardiovascular risks, osteoporosis, and cognitive effects carefully.

BRCA Mutations: Consider PARP inhibitors earlier in treatment pathways.

(Evidence: Moderate)

Key Recommendations

Initiate ADT early in hormone-sensitive disease based on clinical and pathological staging. (Evidence: Strong) 1 26

Use transperineal biopsy when feasible to reduce infection risk. (Evidence: Moderate) 5

Incorporate genomic testing for metastatic disease to guide personalized therapy. (Evidence: Moderate) 27

Monitor PSA levels closely post-ADT initiation and adjust therapy based on response. (Evidence: Strong) 1 26

Consider combined androgen blockade in selected patients for enhanced efficacy. (Evidence: Moderate) 2

Transition to chemotherapy when ADT alone fails, prioritizing docetaxel as first-line. (Evidence: Strong) 26

Evaluate and manage side effects proactively, including cardiovascular and bone health. (Evidence: Moderate) 16 22

Utilize PARP inhibitors in patients with DNA repair gene mutations. (Evidence: Moderate) 7

Regular follow-up with PSA monitoring and clinical assessments to detect early signs of progression. (Evidence: Moderate) 26

Tailor treatment intensity in elderly patients and those with significant comorbidities. (Evidence: Moderate) 35

References

Showing 100 most recent of 1607 indexed papers.

1 Lin DW, Carlsson S, Filson CP, Kim SK, Kirkby E, Konety BR et al.. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026). The Journal of urology 2026. link 2 Petrelli F, Trevisan F, Bruschieri L, Riboldi V, Vavassori I, Seghezzi S et al.. Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses. Cancer treatment reviews 2026. link 3 Rahbar K, Giesel FL, Herrmann K, Yun M, Watabe T, Rudolph I et al.. Efficacy of . Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026. [link 4 Deb AA, Naushad N, Moschonas S, Serag H, Abbas S, Zayed AM et al.. Learning curve's impact on positive surgical margins in RALRP: A prospective cohort study and meta-analysis. The French journal of urology 2026. link 5 Pilatz A, Cornford P, Bonkat G, Kranz J. Transperineal Prostate Biopsy Without Antibiotic Prophylaxis: The New Gold Standard? Recommendations from the European Association of Urology Guidelines on Prostate Cancer and Urological Infections. European urology 2026. link 6 Hajizadeh M, Johnston G. Socioeconomic inequalities in prostate cancer mortality: Response to recent commentary. Cancer epidemiology 2026. link 7 González Enguita C, Pérez Fentes D, Budía Alba A, Lorenzo Gómez MF, Gómez Rivas J, Manso Aparicio C et al.. Prescription of PARP inhibitors (iPARP) in metastatic castration-resistant prostate cancer: a position paper of the Spanish Association of Urology (AEU) and its Uro-Oncology Group (GUO). Actas urologicas espanolas 2026. link 8 Lughezzani G, Celia A, Fasulo V, Marra G, Silvestri T, Vittori G et al.. The Italian Society of Urology Statement on focal therapy for localized prostate cancer. Minerva urology and nephrology 2026. link 9 Lucia MS, Callis S, Tangen C, Almutairi F, Chatzitolios A, Kravtsov O et al.. Whole-Slide Telepathology Grading of Prostate Cancer in Biopsies Using International Society of Urological Pathology Criteria: Interobserver and Intraobserver Concordance and Implications for Active Surveillance. The Journal of urology 2026. link 10 Viñas Dozal JC, Edel Navarro R, Autrán Gómez AM, Ruiz García F, Rojas Hernández VG, Hurtado Capetillo JM et al.. Urology week under the MEDIUVer-UROLATAM model for the development of university-led actions with social impact. Actas urologicas espanolas 2026. link 11 Rezaee ME, Meeks W, Galen E, Helsel A, Pavlovich CP. Examining Variation in Prostate Biopsy Practices in the United States: An Analysis of American Urological Association Census Data. Urology 2026. link 12 Borkowetz A, Wullich B, Saar M, Schmidt-Hegemann N, Linxweiler J. Treatment Strategies in Oligo-Metastatic Prostate Cancer: A Nationwide Survey. Urologia internationalis 2026. link 13 Friedrich NA, Luu M, Gale R, Chaplin A, Polineni R, Shiang A et al.. Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer?. Clinical genitourinary cancer 2026. link 14 Faraj KS, Oerline M, Kaufman SR, Dall C, Srivastava A, Liu X et al.. Impact of In-Office Dispensing Adoption by Urology Practices on Oral Specialty Drug Use in Advanced Prostate Cancer. Cancer medicine 2026. link 15 Chan GJ, Ding CC. Advances in artificial intelligence in prostate cancer pathology. Seminars in diagnostic pathology 2026. link 16 Glaza A, Kennedy A, Jabeer M, Ramanathan S, Obeng A, Zwaans B et al.. Palliative and hospice care in prostate cancer: A scoping review. Urologic oncology 2026. link 17 Guo D, Cai R, Dai T, Lin Y, Zhang D, Hang N et al.. Vascular and neurological toxicity profile of Sipuleucel-T: a large-scale real-world pharmacovigilance study. International journal of surgery (London, England) 2026. link 18 Luo M, Feng C, Lin Y, Chen Y, Pang J. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 19 Yang L, Zeng G, Wang Y, Li F. Adverse events in patients with castration-resistant prostate cancer treated with ra-223: a retrospective pharmacovigilance study. Expert opinion on drug safety 2026. link 20 Rondot A, Crouzet S, Blachier M, Bellocq AS, Abid N, Ruffion A et al.. Hemorrhagic and thrombotic complications following robotic-assisted prostatectomy (RALP) with risk-adapted antithrombotic prophylaxis: A retrospective study. The French journal of urology 2026. link 21 Luo Y, Chen P, Situ M, Zhuang W, Huang J, Wang B et al.. Thrombosis-related gene signature predicts prostate cancer recurrence and immune therapy: insights from retrospective cohorts, bioinformatics, and experimental validation. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026. link 22 Støyten M, Knutsen T, Thune I, Stikbakke E, Wilsgaard T, Eggen AE et al.. Cardiac Function and Prostate Cancer Risk and Prognosis: The PROCA-Life Study. Clinical genitourinary cancer 2026. link 23 Eckstein J, Makary MS, Cataland SR, Young R, Palm R, Pardo DAD et al.. A Case of Hydrogel Spacer Intravasation of the Internal Iliac Vein and Associated Thrombus Formation During Preparation for Prostate Cancer External Beam Radiation Therapy. Practical radiation oncology 2026. link 24 Wang TF, Clarke A, Rath M, Yoo S, Fremont D, Wu C et al.. Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents. Cancer 2026. link 25 Iyer HS, Perlstein M, Joseph SA, Roscoe C, Zeinomar N, Cole AP et al.. Associations of fine particulate matter pollution components with overall, prostate cancer, and cardiovascular disease mortality in men with prostate cancer: A cohort study. Environmental research 2026. link 26 Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R et al.. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2025. link 27 Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL et al.. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025. link 28 Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM et al.. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025. link 29 Raeisvandi A, Omidi S, Javaheri M, Moradi H, Poorolajal J. Updated dose-response meta-analysis of sexual activity and prostate cancer risk. BMC cancer 2025. link 30 Huang S, Chen DC, Qu L, Papa N, Qin K, Adam A et al.. A meta-analysis of Retzius-sparing and hood-technique robot-assisted radical prostatectomy. BJU international 2025. link 31 Tian Z, Zhu Y, Sun X, Cui Q. Meta-analysis of radical prostatectomy outcomes: Oncological control and functional recovery in prostate cancer patients. Medicine 2025. link 32 Wang L, Chen SY, Wan S, Li KP, Li XR, Yang L. Vasectomy and prostate cancer risk: a pooled of cohort studies and Mendelian randomization analysis. BMC cancer 2025. link 33 Bekele D, Martínez-Hernáez A. Qualitative studies on men with prostate cancer: a systematic meta-synthesis. International journal of qualitative studies on health and well-being 2025. link 34 Latorzeff I, Camps-Maléa A, Hennequin C, Chapet O, Pasquier D, Créhange G et al.. External beam radiotherapy for prostatic cancers: 2025 update. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 2025. link 35 Shah RB, Paner GP, Cheng L, De Marzo AM, Magi-Galluzzi C, Varma M et al.. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer. The American journal of surgical pathology 2025. link 36 Marimpietri FS, Tourinho-Barbosa R, Roldan-Testillano R, Batista LT, Sanchez-Salas R. Lower urinary tract symptoms after robot-assisted radical prostatectomy: a systematic review. Journal of robotic surgery 2025. link 37 Bushi G, Ullah A, Khan U, Sayyed H, Shabil M. Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials. International journal of clinical oncology 2025. link 38 Wang K, Wang L, Man J, Yang J, Zhang Y, Wang H et al.. Perioperative and functional outcomes of Retzius-sparing robot-assisted radical prostatectomy vs. conventional robot-assisted radical prostatectomy: evidence based on randomized-controlled trials. Journal of robotic surgery 2025. link 39 Zhu W, Chen W. Examining the Association between ERG/PTEN Expression and Biochemical Recurrence in Prostate Cancer: A Comprehensive Meta-Analysis. Archivos espanoles de urologia 2025. link 40 Liu D, Lin W, Wei C, Huang Y, Chen F, Zhang Y et al.. Exploring the potential clinical value of shear wave elastography in prostate cancer: a meta-analysis. BMC cancer 2025. link 41 Liu Y, Zhang Q, Huang X. Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies. Prostate cancer and prostatic diseases 2025. link 42 Fernández Calvo O, Muñoz Iglesias J, Abou Jokh Casas E, Molina-Díaz A, Anido Herranz U, Casas Nebra J et al.. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of . Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025. link 43 Peinado BRR, Nazário RMF, Frazão DR, Né YGS, Bittencourt LO, Fagundes NCF et al.. Is There Any Association Between Periodontitis and Prostatic Alterations? A Systematic Review. The Prostate 2025. link 44 Zhou Y, He X, Yu Q, Zhong Q. Functional outcomes and complications following salvage radical prostatectomy for post radiotherapy recurrent prostate cancer: A meta-analysis. Medicine 2025. link 45 Takahashi T. Organized prostate cancer screening and the declaration of Helsinki. Scandinavian journal of urology 2025. link 46 Tomita N, Koie T. Radiotherapy for Genitourinary Cancer. Current oncology (Toronto, Ont.) 2025. link 47 Bratt O, Andersson-Säll T, Arnsrud Godtman R, Bjartell A, Gunnarsson O, Lantz A et al.. Movember moustache campaign and participation in Swedish organised prostate cancer testing. Scandinavian journal of urology 2025. link 48 Ventimiglia E, Gedeborg R, Orrason AW, Zaurito P, Garmo H, Stattin P et al.. A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer. Scandinavian journal of urology 2025. link 49 Zaurito P, Garmo H, Gedeborg R, Ahlberg M, Orrason AW, Styrke J et al.. Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study. Scandinavian journal of urology 2025. link 50 Bratt O. Misconceptions about Swedish organised prostate cancer testing. Scandinavian journal of urology 2025. link 51 Rosenberg K. High rate of complications after prostate cancer treatment. The American journal of nursing 2025. link 52 Zattoni F, Novara G, Dal Moro F, Tandogdu Z. Prostate Biopsy: The Transperineal Approach is Better!. European urology focus 2025. link 53 Staffurth JN, Sivell S, Baddeley E, Ahmedzai S, Andreyev HJ, Campbell S et al.. The impact of specialised gastroenterology services for pelvic radiation disease (PRD): Results from the prospective multi-centre EAGLE study. PloS one 2025. link 54 Srivastava A, Liu X, Maganty A, Kaufman SR, Shay A, Oerline M et al.. Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare. Cancer 2025. link 55 Shore N, Brown G, Lowentritt B, O'Donnell L, Wilt W, Burbage S et al.. Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology. Urology 2025. link 56 Joo S, Lu K, Park J, Rho MJ, Park YH. Changes in urologic research from a new perspective: Text mining analysis of publication topics. Investigative and clinical urology 2025. link 57 Shah RB, Paner GP, Cheng L, De Marzo AM, Magi-Galluzzi C, Varma M et al.. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. European urology 2025. link 58 Williams Z, Saad J, Ayeni FE, Wang H, Zhong W, Gendy R et al.. Comparing outcomes of robotic-assisted radical prostatectomy by specialists and trainees using a modular training approach. Journal of robotic surgery 2025. link 59 Gaylis FD, Leapman MS, Ellis SD, Hu S, Cooperberg MR, Loeb S et al.. Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients With Low-Risk Prostate Cancer in the Community Practice. Urology practice 2025. link 60 Bisset B, Shriram T, Davuluri M, Azar H, Beilan J, Amin R et al.. Applications and Outcomes of Telehealth and Integrated Care in Men's Health Urology. Journal of medical Internet research 2025. link 61 Lowentritt B, Appukkuttan S, Lazarou N, O'Donnell L, Eller J, Grant K et al.. Use of Doublet or Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Across Community-Based Urology Settings in the United States. Urology practice 2025. link 62 Vatrano S, Pepe P, Pepe L, Vella N, Alario C, Chiarandà A et al.. BRCA mutations and prostate cancer: should urologist improve daily clinical practice?. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2025. link 63 Badalato GM, Khan S, Gorroochurn P, Lemack GE, McKiernan JM, Hruby G et al.. The Impact of American Board of Urology Certification on Post-operative Outcomes for Patients: Assessing National Trends. Urology 2025. link 64 Covas Moschovas M, Saikali S, Sandri M, Bravi C, Falagario U, Nathan A et al.. Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group. European urology 2025. link 65 Armstrong AJ, Taylor A, Haffner MC, Abida W, Bryce AH, Karsh LI et al.. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). Prostate cancer and prostatic diseases 2025. link 66 Arenas-Gallo C, Goldman M, Millot JC, McCann J, Bohorquez-Caballero AD, Rhodes S et al.. Increasing Utilization of Sedation for Prostate Biopsies: National Trends, Predictors, and Patient Cost. Urology 2025. link 67 Deman F, Broeckx G, Declercq S, Degotte Q, Raymaekers J, Salgado R et al.. Practical implementation of AI in a non-academic, non-commercial Pathology laboratory: Real world experience and lessons learned. Histopathology 2025. link 68 Nourbakshs M, Du L, Acosta AM, Alaghehbandan R, Amin A, Amin MB et al.. Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists. Histopathology 2025. link 69 Yang H, Finkelstein J. Using Big Data to Uncover Drug-Gene Interaction in Patients with Prostate Cancer. Studies in health technology and informatics 2025. link 70 Lee J, Song M, Leem S, Kim JY, Chung BI, Shim SR et al.. Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data. PloS one 2025. link 71 Jin Y, Zhang Y, Wang M, Bai X, Ping H, Xing N. Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto. BMC cancer 2025. link 72 Wang W, Dong Z, Hong B, Guan X, Wang Y, Sun Z et al.. Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis. Cancer medicine 2025. link 73 Jia W, Wang T. Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data. Scientific reports 2025. link 74 Liu W, Song X, Wang L, Liu J, Du Q. Unveiling the hidden cardiovascular risk of sipuleucel-T: a pharmacovigilance analysis using the FDA Adverse Event Reporting System, 2010-2025. Frontiers in immunology 2025. link 75 Yamada T, Tanaka S, Noda T, Urashima K, Fujimoto A, Kohda Y et al.. Disproportionality analysis of flutamide- or bicalutamide-induced liver injury with and without steroids by using the Japanese Adverse Drug Event Report database. International journal of clinical pharmacy 2025. link 76 Chen Y, Lu W, Liao R, Zhang X, Chen W, Wang J et al.. Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study. PloS one 2025. link 77 de Moraes FCA, Sano VKT, Dantas CR, Hoffmeister N, Kelly FA, Burbano RMR. A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025. link 78 Marrone MT, Prizment AE, Wang W, Bhanat E, Butler KR, Couper D et al.. Blood Pressure, Hypertension, and Antihypertensive Medication Use and Risk of Total and Fatal Prostate Cancer in Black and White Men in the Atherosclerosis Risk in Communities (ARIC) Study. Journal of racial and ethnic health disparities 2025. link 79 Matsukawa A, Yanagisawa T, Parizi MK, Laukhtina E, Klemm J, Fazekas T et al.. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate cancer and prostatic diseases 2025. link 80 Mendelson JL, Kassab J, Westbrook P, Yang K, Corcoran A. Successful treatment of rare vaso-vesical fistula with minimally invasive measures despite prior history of radiotherapy: a case report. The Canadian journal of urology 2025. link 81 Daly W, Pelzman D, Ogagan PD, Jackman SV. Pseudoaneurysm after prostate biopsy: case report. The Canadian journal of urology 2025. link 82 Moryousef J, Duivenvoorden W, Leong D, Pinthus JH. Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies. Prostate cancer and prostatic diseases 2025. link 83 Patel S, Zhu K, Dave CV, Ghajar M, Zhang Y, Saraiya B et al.. Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies. European urology oncology 2025. link 84 Koutroumpakis E, Patel R, Khadke S, Bedrosian A, Kumar A, Kong Y et al.. Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. Cardiovascular drugs and therapy 2025. link 85 Chan JSK, Lee YHA, Leung CH, Leung DKW, Dee EC, Ng K et al.. Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study. Prostate cancer and prostatic diseases 2025. link 86 Leong DP, Cirne F, Pinthus JH. Cardiovascular Risk in Prostate Cancer. Cardiology clinics 2025. link 87 Fanaroff AC, Orr JA, Anucha C, Kim E, Rareshide C, Echevarria M et al.. A randomized controlled trial of gamification to increase physical activity among black and Hispanic breast and prostate cancer survivors: Rationale and design of the ALLSTAR clinical trial. American heart journal 2025. link 88 Amirmokri AJ, Loffredo CA, Makambi KH, Dawson NA. Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis. BMC cancer 2025. link 89 Vitor GP, Carvalho AP, Esteves Lima RP, Miconi WG, Costa FO, Cota LOM. Association between periodontitis and prostate cancer: A case-control study. Journal of periodontology 2025. link 90 Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al.. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology 2024. link 91 Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al.. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European urology 2024. link 92 Zhen L, Juan W, Tianrui F, Yuliang C, Zhien Z, Yi Z et al.. A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?. Critical reviews in oncology/hematology 2024. link 93 Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V et al.. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. European urology 2024. link 94 Fang Y, Xia L, Lu H, He H. Meta-Analysis of Transperineal and Transrectal Ultrasound-Guided Prostate Biopsy in the Detection of Prostate Cancer. Archivos espanoles de urologia 2024. link 95 Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH et al.. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. The Journal of urology 2024. link 96 Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T et al.. Japanese clinical practice guidelines for prostate cancer 2023. International journal of urology : official journal of the Japanese Urological Association 2024. link 97 Ploussard G, Dariane C, Mathieu R, Baboudjian M, Barret E, Brureau L et al.. French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance. The French journal of urology 2024. link 98 Ploussard G, Baboudjian M, Barret E, Brureau L, Fiard G, Fromont G et al.. French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease. The French journal of urology 2024. link 99 Okwor CJ, Okwor VC, Meka IA, Emedoh AE, Nweke M. Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review. Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2024. link 100 Deville C, Kamran SC, Morgan SC, Yamoah K, Vapiwala N. Radiation Therapy Summary of the AUA/ASTRO Guideline on Clinically Localized Prostate Cancer. Practical radiation oncology 2024. link

Original source

[1]
Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026). — Lin DW, Carlsson S, Filson CP, Kim SK, Kirkby E, Konety BR et al. The Journal of urology (2026)
[2]
Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses. — Petrelli F, Trevisan F, Bruschieri L, Riboldi V, Vavassori I, Seghezzi S et al. Cancer treatment reviews (2026)
[3]
Efficacy of [ — Rahbar K, Giesel FL, Herrmann K, Yun M, Watabe T, Rudolph I et al. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2026)
[4]
Learning curve's impact on positive surgical margins in RALRP: A prospective cohort study and meta-analysis. — Deb AA, Naushad N, Moschonas S, Serag H, Abbas S, Zayed AM et al. The French journal of urology (2026)
[5]
Transperineal Prostate Biopsy Without Antibiotic Prophylaxis: The New Gold Standard? Recommendations from the European Association of Urology Guidelines on Prostate Cancer and Urological Infections. — Pilatz A, Cornford P, Bonkat G, Kranz J European urology (2026)
[6]
Socioeconomic inequalities in prostate cancer mortality: Response to recent commentary. — Hajizadeh M, Johnston G Cancer epidemiology (2026)
[7]
Prescription of PARP inhibitors (iPARP) in metastatic castration-resistant prostate cancer: a position paper of the Spanish Association of Urology (AEU) and its Uro-Oncology Group (GUO). — González Enguita C, Pérez Fentes D, Budía Alba A, Lorenzo Gómez MF, Gómez Rivas J, Manso Aparicio C et al. Actas urologicas espanolas (2026)
[8]
The Italian Society of Urology Statement on focal therapy for localized prostate cancer. — Lughezzani G, Celia A, Fasulo V, Marra G, Silvestri T, Vittori G et al. Minerva urology and nephrology (2026)
[9]
Whole-Slide Telepathology Grading of Prostate Cancer in Biopsies Using International Society of Urological Pathology Criteria: Interobserver and Intraobserver Concordance and Implications for Active Surveillance. — Lucia MS, Callis S, Tangen C, Almutairi F, Chatzitolios A, Kravtsov O et al. The Journal of urology (2026)
[10]
Urology week under the MEDIUVer-UROLATAM model for the development of university-led actions with social impact. — Viñas Dozal JC, Edel Navarro R, Autrán Gómez AM, Ruiz García F, Rojas Hernández VG, Hurtado Capetillo JM et al. Actas urologicas espanolas (2026)
[11]
Examining Variation in Prostate Biopsy Practices in the United States: An Analysis of American Urological Association Census Data. — Rezaee ME, Meeks W, Galen E, Helsel A, Pavlovich CP Urology (2026)
[12]
Treatment Strategies in Oligo-Metastatic Prostate Cancer: A Nationwide Survey. — Borkowetz A, Wullich B, Saar M, Schmidt-Hegemann N, Linxweiler J Urologia internationalis (2026)
[13]
Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer? — Friedrich NA, Luu M, Gale R, Chaplin A, Polineni R, Shiang A et al. Clinical genitourinary cancer (2026)
[14]
Impact of In-Office Dispensing Adoption by Urology Practices on Oral Specialty Drug Use in Advanced Prostate Cancer. — Faraj KS, Oerline M, Kaufman SR, Dall C, Srivastava A, Liu X et al. Cancer medicine (2026)
[15]
Advances in artificial intelligence in prostate cancer pathology. — Chan GJ, Ding CC Seminars in diagnostic pathology (2026)
[16]
Palliative and hospice care in prostate cancer: A scoping review. — Glaza A, Kennedy A, Jabeer M, Ramanathan S, Obeng A, Zwaans B et al. Urologic oncology (2026)
[17]
Vascular and neurological toxicity profile of Sipuleucel-T: a large-scale real-world pharmacovigilance study. — Guo D, Cai R, Dai T, Lin Y, Zhang D, Hang N et al. International journal of surgery (London, England) (2026)
[18]
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel. — Luo M, Feng C, Lin Y, Chen Y, Pang J Naunyn-Schmiedeberg's archives of pharmacology (2026)
[19]
Adverse events in patients with castration-resistant prostate cancer treated with ra-223: a retrospective pharmacovigilance study. — Yang L, Zeng G, Wang Y, Li F Expert opinion on drug safety (2026)
[20]
Hemorrhagic and thrombotic complications following robotic-assisted prostatectomy (RALP) with risk-adapted antithrombotic prophylaxis: A retrospective study. — Rondot A, Crouzet S, Blachier M, Bellocq AS, Abid N, Ruffion A et al. The French journal of urology (2026)
[21]
Thrombosis-related gene signature predicts prostate cancer recurrence and immune therapy: insights from retrospective cohorts, bioinformatics, and experimental validation. — Luo Y, Chen P, Situ M, Zhuang W, Huang J, Wang B et al. Inflammation research : official journal of the European Histamine Research Society ... [et al.] (2026)
[22]
Cardiac Function and Prostate Cancer Risk and Prognosis: The PROCA-Life Study. — Støyten M, Knutsen T, Thune I, Stikbakke E, Wilsgaard T, Eggen AE et al. Clinical genitourinary cancer (2026)
[23]
A Case of Hydrogel Spacer Intravasation of the Internal Iliac Vein and Associated Thrombus Formation During Preparation for Prostate Cancer External Beam Radiation Therapy. — Eckstein J, Makary MS, Cataland SR, Young R, Palm R, Pardo DAD et al. Practical radiation oncology (2026)
[24]
Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents. — Wang TF, Clarke A, Rath M, Yoo S, Fremont D, Wu C et al. Cancer (2026)
[25]
Associations of fine particulate matter pollution components with overall, prostate cancer, and cardiovascular disease mortality in men with prostate cancer: A cohort study. — Iyer HS, Perlstein M, Joseph SA, Roscoe C, Zeinomar N, Cole AP et al. Environmental research (2026)
[26]
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. — Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R et al. Journal of the National Comprehensive Cancer Network : JNCCN (2025)
[27]
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. — Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025)
[28]
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. — Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025)
[29]
Updated dose-response meta-analysis of sexual activity and prostate cancer risk. — Raeisvandi A, Omidi S, Javaheri M, Moradi H, Poorolajal J BMC cancer (2025)
[30]
A meta-analysis of Retzius-sparing and hood-technique robot-assisted radical prostatectomy. — Huang S, Chen DC, Qu L, Papa N, Qin K, Adam A et al. BJU international (2025)
[31]
Meta-analysis of radical prostatectomy outcomes: Oncological control and functional recovery in prostate cancer patients. — Tian Z, Zhu Y, Sun X, Cui Q Medicine (2025)
[32]
Vasectomy and prostate cancer risk: a pooled of cohort studies and Mendelian randomization analysis. — Wang L, Chen SY, Wan S, Li KP, Li XR, Yang L BMC cancer (2025)
[33]
Qualitative studies on men with prostate cancer: a systematic meta-synthesis. — Bekele D, Martínez-Hernáez A International journal of qualitative studies on health and well-being (2025)
[34]
External beam radiotherapy for prostatic cancers: 2025 update. — Latorzeff I, Camps-Maléa A, Hennequin C, Chapet O, Pasquier D, Créhange G et al. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025)
[35]
Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer. — Shah RB, Paner GP, Cheng L, De Marzo AM, Magi-Galluzzi C, Varma M et al. The American journal of surgical pathology (2025)
[36]
Lower urinary tract symptoms after robot-assisted radical prostatectomy: a systematic review. — Marimpietri FS, Tourinho-Barbosa R, Roldan-Testillano R, Batista LT, Sanchez-Salas R Journal of robotic surgery (2025)
[37]
Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials. — Bushi G, Ullah A, Khan U, Sayyed H, Shabil M International journal of clinical oncology (2025)
[38]
Perioperative and functional outcomes of Retzius-sparing robot-assisted radical prostatectomy vs. conventional robot-assisted radical prostatectomy: evidence based on randomized-controlled trials. — Wang K, Wang L, Man J, Yang J, Zhang Y, Wang H et al. Journal of robotic surgery (2025)
[39]
Examining the Association between ERG/PTEN Expression and Biochemical Recurrence in Prostate Cancer: A Comprehensive Meta-Analysis. — Zhu W, Chen W Archivos espanoles de urologia (2025)
[40]
Exploring the potential clinical value of shear wave elastography in prostate cancer: a meta-analysis. — Liu D, Lin W, Wei C, Huang Y, Chen F, Zhang Y et al. BMC cancer (2025)
[41]
Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies. — Liu Y, Zhang Q, Huang X Prostate cancer and prostatic diseases (2025)
[42]
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of — Fernández Calvo O, Muñoz Iglesias J, Abou Jokh Casas E, Molina-Díaz A, Anido Herranz U, Casas Nebra J et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2025)
[43]
Is There Any Association Between Periodontitis and Prostatic Alterations? A Systematic Review. — Peinado BRR, Nazário RMF, Frazão DR, Né YGS, Bittencourt LO, Fagundes NCF et al. The Prostate (2025)
[44]
Functional outcomes and complications following salvage radical prostatectomy for post radiotherapy recurrent prostate cancer: A meta-analysis. — Zhou Y, He X, Yu Q, Zhong Q Medicine (2025)
[45]
Organized prostate cancer screening and the declaration of Helsinki. — Takahashi T Scandinavian journal of urology (2025)
[46]
Radiotherapy for Genitourinary Cancer. — Tomita N, Koie T Current oncology (Toronto, Ont.) (2025)
[47]
Movember moustache campaign and participation in Swedish organised prostate cancer testing. — Bratt O, Andersson-Säll T, Arnsrud Godtman R, Bjartell A, Gunnarsson O, Lantz A et al. Scandinavian journal of urology (2025)
[48]
A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer. — Ventimiglia E, Gedeborg R, Orrason AW, Zaurito P, Garmo H, Stattin P et al. Scandinavian journal of urology (2025)
[49]
Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study. — Zaurito P, Garmo H, Gedeborg R, Ahlberg M, Orrason AW, Styrke J et al. Scandinavian journal of urology (2025)
[50]
Misconceptions about Swedish organised prostate cancer testing. — Bratt O Scandinavian journal of urology (2025)
[51]
High rate of complications after prostate cancer treatment. — Rosenberg K The American journal of nursing (2025)
[52]
Prostate Biopsy: The Transperineal Approach is Better! — Zattoni F, Novara G, Dal Moro F, Tandogdu Z European urology focus (2025)
[53]
The impact of specialised gastroenterology services for pelvic radiation disease (PRD): Results from the prospective multi-centre EAGLE study. — Staffurth JN, Sivell S, Baddeley E, Ahmedzai S, Andreyev HJ, Campbell S et al. PloS one (2025)
[54]
Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare. — Srivastava A, Liu X, Maganty A, Kaufman SR, Shay A, Oerline M et al. Cancer (2025)
[55]
Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology. — Shore N, Brown G, Lowentritt B, O'Donnell L, Wilt W, Burbage S et al. Urology (2025)
[56]
Changes in urologic research from a new perspective: Text mining analysis of publication topics. — Joo S, Lu K, Park J, Rho MJ, Park YH Investigative and clinical urology (2025)
[57]
Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. — Shah RB, Paner GP, Cheng L, De Marzo AM, Magi-Galluzzi C, Varma M et al. European urology (2025)
[58]
Comparing outcomes of robotic-assisted radical prostatectomy by specialists and trainees using a modular training approach. — Williams Z, Saad J, Ayeni FE, Wang H, Zhong W, Gendy R et al. Journal of robotic surgery (2025)
[59]
Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients With Low-Risk Prostate Cancer in the Community Practice. — Gaylis FD, Leapman MS, Ellis SD, Hu S, Cooperberg MR, Loeb S et al. Urology practice (2025)
[60]
Applications and Outcomes of Telehealth and Integrated Care in Men's Health Urology. — Bisset B, Shriram T, Davuluri M, Azar H, Beilan J, Amin R et al. Journal of medical Internet research (2025)
[61]
Use of Doublet or Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Across Community-Based Urology Settings in the United States. — Lowentritt B, Appukkuttan S, Lazarou N, O'Donnell L, Eller J, Grant K et al. Urology practice (2025)
[62]
BRCA mutations and prostate cancer: should urologist improve daily clinical practice? — Vatrano S, Pepe P, Pepe L, Vella N, Alario C, Chiarandà A et al. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica (2025)
[63]
The Impact of American Board of Urology Certification on Post-operative Outcomes for Patients: Assessing National Trends. — Badalato GM, Khan S, Gorroochurn P, Lemack GE, McKiernan JM, Hruby G et al. Urology (2025)
[64]
Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group. — Covas Moschovas M, Saikali S, Sandri M, Bravi C, Falagario U, Nathan A et al. European urology (2025)
[65]
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). — Armstrong AJ, Taylor A, Haffner MC, Abida W, Bryce AH, Karsh LI et al. Prostate cancer and prostatic diseases (2025)
[66]
Increasing Utilization of Sedation for Prostate Biopsies: National Trends, Predictors, and Patient Cost. — Arenas-Gallo C, Goldman M, Millot JC, McCann J, Bohorquez-Caballero AD, Rhodes S et al. Urology (2025)
[67]
Practical implementation of AI in a non-academic, non-commercial Pathology laboratory: Real world experience and lessons learned. — Deman F, Broeckx G, Declercq S, Degotte Q, Raymaekers J, Salgado R et al. Histopathology (2025)
[68]
Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists. — Nourbakshs M, Du L, Acosta AM, Alaghehbandan R, Amin A, Amin MB et al. Histopathology (2025)
[69]
Using Big Data to Uncover Drug-Gene Interaction in Patients with Prostate Cancer. — Yang H, Finkelstein J Studies in health technology and informatics (2025)
[70]
Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data. — Lee J, Song M, Leem S, Kim JY, Chung BI, Shim SR et al. PloS one (2025)
[71]
Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto — Jin Y, Zhang Y, Wang M, Bai X, Ping H, Xing N BMC cancer (2025)
[72]
Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis. — Wang W, Dong Z, Hong B, Guan X, Wang Y, Sun Z et al. Cancer medicine (2025)
[73]
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data. — Jia W, Wang T Scientific reports (2025)
[74]
Unveiling the hidden cardiovascular risk of sipuleucel-T: a pharmacovigilance analysis using the FDA Adverse Event Reporting System, 2010-2025. — Liu W, Song X, Wang L, Liu J, Du Q Frontiers in immunology (2025)
[75]
Disproportionality analysis of flutamide- or bicalutamide-induced liver injury with and without steroids by using the Japanese Adverse Drug Event Report database. — Yamada T, Tanaka S, Noda T, Urashima K, Fujimoto A, Kohda Y et al. International journal of clinical pharmacy (2025)
[76]
Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study. — Chen Y, Lu W, Liao R, Zhang X, Chen W, Wang J et al. PloS one (2025)
[77]
A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer. — de Moraes FCA, Sano VKT, Dantas CR, Hoffmeister N, Kelly FA, Burbano RMR Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2025)
[78]
Blood Pressure, Hypertension, and Antihypertensive Medication Use and Risk of Total and Fatal Prostate Cancer in Black and White Men in the Atherosclerosis Risk in Communities (ARIC) Study. — Marrone MT, Prizment AE, Wang W, Bhanat E, Butler KR, Couper D et al. Journal of racial and ethnic health disparities (2025)
[79]
Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. — Matsukawa A, Yanagisawa T, Parizi MK, Laukhtina E, Klemm J, Fazekas T et al. Prostate cancer and prostatic diseases (2025)
[80]
Successful treatment of rare vaso-vesical fistula with minimally invasive measures despite prior history of radiotherapy: a case report. — Mendelson JL, Kassab J, Westbrook P, Yang K, Corcoran A The Canadian journal of urology (2025)
[81]
Pseudoaneurysm after prostate biopsy: case report. — Daly W, Pelzman D, Ogagan PD, Jackman SV The Canadian journal of urology (2025)
[82]
Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies. — Moryousef J, Duivenvoorden W, Leong D, Pinthus JH Prostate cancer and prostatic diseases (2025)
[83]
Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies. — Patel S, Zhu K, Dave CV, Ghajar M, Zhang Y, Saraiya B et al. European urology oncology (2025)
[84]
Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. — Koutroumpakis E, Patel R, Khadke S, Bedrosian A, Kumar A, Kong Y et al. Cardiovascular drugs and therapy (2025)
[85]
Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: a retrospective cohort study. — Chan JSK, Lee YHA, Leung CH, Leung DKW, Dee EC, Ng K et al. Prostate cancer and prostatic diseases (2025)
[86]
Cardiovascular Risk in Prostate Cancer. — Leong DP, Cirne F, Pinthus JH Cardiology clinics (2025)
[87]
A randomized controlled trial of gamification to increase physical activity among black and Hispanic breast and prostate cancer survivors: Rationale and design of the ALLSTAR clinical trial. — Fanaroff AC, Orr JA, Anucha C, Kim E, Rareshide C, Echevarria M et al. American heart journal (2025)
[88]
Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis. — Amirmokri AJ, Loffredo CA, Makambi KH, Dawson NA BMC cancer (2025)
[89]
Association between periodontitis and prostate cancer: A case-control study. — Vitor GP, Carvalho AP, Esteves Lima RP, Miconi WG, Costa FO, Cota LOM Journal of periodontology (2025)
[90]
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. — Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al. European urology (2024)
[91]
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. — Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al. European urology (2024)
[92]
A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately? — Zhen L, Juan W, Tianrui F, Yuliang C, Zhien Z, Yi Z et al. Critical reviews in oncology/hematology (2024)
[93]
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. — Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V et al. European urology (2024)
[94]
Meta-Analysis of Transperineal and Transrectal Ultrasound-Guided Prostate Biopsy in the Detection of Prostate Cancer. — Fang Y, Xia L, Lu H, He H Archivos espanoles de urologia (2024)
[95]
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. — Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH et al. The Journal of urology (2024)
[96]
Japanese clinical practice guidelines for prostate cancer 2023. — Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T et al. International journal of urology : official journal of the Japanese Urological Association (2024)
[97]
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance. — Ploussard G, Dariane C, Mathieu R, Baboudjian M, Barret E, Brureau L et al. The French journal of urology (2024)
[98]
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease. — Ploussard G, Baboudjian M, Barret E, Brureau L, Fiard G, Fromont G et al. The French journal of urology (2024)
[99]
Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review. — Okwor CJ, Okwor VC, Meka IA, Emedoh AE, Nweke M Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2024)
[100]
Radiation Therapy Summary of the AUA/ASTRO Guideline on Clinically Localized Prostate Cancer. — Deville C, Kamran SC, Morgan SC, Yamoah K, Vapiwala N Practical radiation oncology (2024)

Share:Twitter Reddit LinkedIn